Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Days Payable distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's Days Payable falls into.
Medigen Vaccine Biologics Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Medigen Vaccine Biologics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Vaccine Biologics (ROCO:6547) has a Days Payable of 50.23 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medigen Vaccine Biologics and its competitors. This is near median its historical median of 47.99. Over the past decade, Medigen Vaccine Biologics' Days Payable has ranged from 17.61 to 1,088.02. According to the industry distribution chart, Medigen Vaccine Biologics ranks #622 out of 704 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Medigen Vaccine Biologics' Days Payable too high?
Medigen Vaccine Biologics' current Days Payable of 50.23 is near median its 10-year median of 47.99. Over the past 10 years, this metric has ranged from a low of 17.61 to a high of 1,088.02. The Biotechnology industry median Days Payable is 112.72. Medigen Vaccine Biologics' value of 50.23 is 55.4% below this industry median. Based on the distribution chart, Medigen Vaccine Biologics ranks #622 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #622 out of 704 companies for Days Payable. This places Medigen Vaccine Biologics in the lower half of its industry. The industry median Days Payable is 112.72. Medigen Vaccine Biologics' value of 50.23 is 55.4% below this benchmark. Historically, Medigen Vaccine Biologics' own Days Payable has ranged from 17.61 to 1,088.02 over the past decade. While the company's 10-year median is 47.99 vs. the industry median of 112.72, Medigen Vaccine Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Vaccine Biologics's current Days Payable of 50.23 is 55.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medigen Vaccine Biologics and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Vaccine Biologics's current Days Payable is 50.23, which is near median its own 10-year median of 47.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$58.87, compared to a current price of NT$52.20 — trading 11.3% below its estimated fair value. The current Days Payable is 50.23, which is near median its 10-year median of 47.99 and 55.4% below the Biotechnology industry median of 112.72. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Days Payable is 50.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$52.20 is trading 11.3% below its estimated GF Value™ of NT$58.87.
GuruFocus considers Medigen Vaccine Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:6547:
Days Payable: 50.23 (near median its 10-year median of 47.99)
GF Value™: NT$58.87 vs. price of NT$52.20 (11.3% below fair value)
Industry Position: 55.4% below the Biotechnology median (#622 of 704)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score
Get the complete analysis for ROCO:6547
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
